Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
4DMedical Ltd ( (AU:4DX) ) has provided an update.
4DMedical Limited has secured $30.2 million in funding through an underwriting agreement with Bell Potter Securities Limited, ensuring the exercise of all 4DXO listed options. This funding boosts the company’s pro forma cash balance to $63.7 million as of September 2025. The company is experiencing significant interest in its CT:VQ™ technology, with multiple contract discussions underway, positioning 2026 as a potentially transformative year. This financial backing supports 4DMedical’s strategy to commercialize CT:VQ™ and establish key U.S. academic medical centers as reference sites, reinforcing its market position and growth trajectory.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
More about 4DMedical Ltd
4DMedical Limited (ASX:4DX) is a global medical technology company specializing in advanced imaging and artificial intelligence to revolutionize respiratory care. Its patented XV Technology® enhances standard scans to provide detailed insights for early detection and monitoring of lung diseases. The company’s software portfolio, including FDA-cleared XV Lung Ventilation Analysis Software and CT:VQ™ solution, integrates seamlessly into hospital systems to improve physician productivity and patient care. With the integration of AI capabilities from its acquisition of Imbio, 4DMedical is at the forefront of redefining respiratory disease management worldwide.
Average Trading Volume: 5,333,124
Technical Sentiment Signal: Buy
Current Market Cap: A$1.03B
Find detailed analytics on 4DX stock on TipRanks’ Stock Analysis page.